Melbourne, Australia, 09 January 2023: OccuRx, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases, are pleased to announce Executive Chair, Professor Darren Kelly, and Chief Commercial Officer Dr Gareth Lewis will be participating in the 41st Annual J.P. Morgan Healthcare Conference and associated partnering meetings from 9 – 12 January 2023 in San Francisco, California.
“We are excited to attend this year’s J.P Morgan Healthcare conference and looking forward to continuing our discussions with pharmaceutical partners and other biotechnology investment firms about recent scientific advancements and the clinical development program for our lead candidate OCX063” said Professor Darren Kelly, Executive Chair of OccuRx.
The OccuRx team will highlight their scientific advancements in anti-inflammatory and anti-fibrotic therapies, including important recent clinical development progress and plans with its novel therapeutic platform.
OccuRx has designed a platform of candidate drugs and validated the role of a novel receptor which mediates signalling pathways associated with inflammation and fibrosis. These targeted drugs have established proof of concept as potential treatments for multiple fibrotic diseases including serious and chronic conditions impacting the kidney, lung, eye, and skin. The morbidity and mortality impact of fibrotic diseases is substantial, ultimately causing 45% of all deaths globally. OccuRx is seeking to combine these innovative therapeutics with biomarkers and genetic analysis to identify those patients most likely to benefit from treatment
The company’s most advanced molecule drug candidate, OCX063, is being developed as a first-in-class oral therapy for the treatment for both kidney and ocular diseases. OCX063, is a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation.
The J.P. Morgan Healthcare Conference is the largest healthcare investment conference in the United States. It brings together industry leaders, investors, fast-growth companies, and emerging technology creators in healthcare.